Clinuvel Pharmaceuticals (CUV) Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CUV from our risk checks.
CUV Community Fair Values
Create NarrativeSee what 114 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$9.09 |
| 52 Week High | AU$14.00 |
| 52 Week Low | AU$8.96 |
| Beta | 0.68 |
| 1 Month Change | -9.37% |
| 3 Month Change | -28.09% |
| 1 Year Change | -14.25% |
| 3 Year Change | -55.44% |
| 5 Year Change | -70.00% |
| Change since IPO | 809.00% |
Recent News & Updates
Recent updates
Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem
Sep 03
It's A Story Of Risk Vs Reward With Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jul 21
Expansion Into Vitiligo Treatments And PhotoCosmetics Will Unlock Future Opportunities
Expansion into new therapeutic areas and markets, including vitiligo treatment and North America, is projected to drive significant revenue growth.If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27Shareholder Returns
| CUV | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0.8% | 0.9% | 4.4% |
| 1Y | -14.2% | -40.4% | 15.5% |
Return vs Industry: CUV exceeded the Australian Biotechs industry which returned -40.4% over the past year.
Return vs Market: CUV underperformed the Australian Market which returned 15.5% over the past year.
Price Volatility
| CUV volatility | |
|---|---|
| CUV Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 10.4% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 4.5% |
Stable Share Price: CUV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CUV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| CUV fundamental statistics | |
|---|---|
| Market cap | AU$457.33m |
| Earnings (TTM) | AU$32.54m |
| Revenue (TTM) | AU$96.30m |
Is CUV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUV income statement (TTM) | |
|---|---|
| Revenue | AU$96.30m |
| Cost of Revenue | AU$9.99m |
| Gross Profit | AU$86.32m |
| Other Expenses | AU$53.78m |
| Earnings | AU$32.54m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 89.63% |
| Net Profit Margin | 33.79% |
| Debt/Equity Ratio | 0% |
How did CUV perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 14:05 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clinuvel Pharmaceuticals Limited is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Madeleine Williams | Canaccord Genuity |